Brief: Haemato Says Terminates Cooperation With Korean Manufacturer Huons Biopharma; To Discontinue Project For A Proprietary Botulinum Toxin
15/11/2023 18:51
Nov 15 (Reuters) - Haemato AG HAEk.DE :
* EQS-ADHOC: TERMINATION OF THE BOTULINUM TOXIN PROJECT
* DECISION HAS NO IMPACT ON COMPANY'S OPERATING BUSINESS.
* HAEMATO - DUE TO NEW FINDINGS ON CHANGED MARKET
CONDITIONS,
UPDATED VALIDATION OF PROFITABILITY OF CO'S OWN BOTULINUM TOXIN
PROJECT WAS CARRIED OUT
* TERMINATE COOPERATION WITH KOREAN MANUFACTURER HUONS
BIOPHARMA
AND TO DISCONTINUE PROJECT FOR A PROPRIETARY BOTULINUM TOXIN
Source text for Eikon: ID:nEQ8HGd8ra
Further company coverage: HAEk.DE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Haemato AG
See all newsBrief: HAEMATO Raises FY EBIT Guidance to EUR 10-12 Million
Brief: Haemato Says Terminates Cooperation With Korean Manufacturer Huons Biopharma; To Discontinue Project For A Proprietary Botulinum Toxin
Brief: Haemato Q1 EBITDA At EUR 2.3 Mln
Brief: Haemato To Propose Dividend Of EUR 1.10 Per Share
Brief: Haemato Preliminary Consolidated FY EBIT Up At EUR 11.2 Mln